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Abstract 
We recently reported the discovery of a novel protein stabilizing dipeptide, glycyl-D-asparagine, 
through a structure-based approach. As the starting hypothesis leading to the discovery, we postulated 
a stabilizing effect achieved by binding of the dipeptide to an aggregation prone region on the protein’s 
surface. Here we present a detailed study of the interaction mechanism between the dipeptide and 
Interferon-alpha-2A (IFN) through the construction of a Markov state model from molecular dynamics 
trajectories. We identify multiple binding sites and compare these to aggregation prone regions. 
Additionally, we calculate the lifetime of the protein-excipient complex. If the excipient remained 
bound to the IFN after administration, it could alter the protein’s therapeutic efficacy.  We establish 
that the lifetime of the complex between IFN and glycyl-D-asparagine is extremely short. Under these 
circumstances, stabilization by stoichiometric binding is consequently no impediment for a safe use of 
an excipient. 
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Introduction 
Small molecules are commonly found in therapeutic protein drug formulations as co-solutes with the 
intend to stabilize the drug product among other against chemical degradation or aggregation of the 
therapeutic protein. Opposed to native self-association, protein aggregation proceeds by multiple 
steps that among other involve a partial or complete unfolding of the protein[1].  
Two commonly accepted mechanisms of stabilization of a protein against aggregation by a small 
molecular co-solute are preferential exclusion and stoichiometric binding [2–6].  Preferential exclusion 
describes an entropically driven rise of chemical potential of both, protein and co-solute molecules 
relative to their separate solutions. The increase in chemical potential manifests by a reduced 
concentration of co-solute in proximity to the protein surface relative to the bulk solution. Protein 
unfolding will lead to an increased exposure of protein surface, increasing the unfavorable exclusion 
of co-solute. The protein’s native state is therefore preferred to the non-native. The stabilizing effect 
of a diverse group of co-solutes such as sugars, polyols, amino acids, methylamines and inorganic salts 
on proteins has been well established and traced back to preferential exclusion as mechanism of action 
[2,7]. Preferential exclusion is observed for weakly interacting co-solutes that require to be present at 
high concentration (above 200 mM) in order to benefit protein stability. 
Stoichiometrically interacting co-solutes are known to stabilize proteins by binding preferentially to 
the native protein structure relative to the unfolded one, which can for example be determined by 
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differential scanning fluorimetry or calorimetry and results in a shift of the infliction point of the 
characteristic unfolding curve (Tm) [8]. 
The large majority of pharmaceutical excipients act through the mechanism of preferential exclusion, 
which has the intrinsic benefit that their application is not limited to a single protein but across many 
if not all. Developing excipients that act as stoichiometric stabilizers has largely been neglected, despite 
the potential to provide a complementary mean to stabilize a protein[9]. 
We previously described the discovery of an outstanding stabilizing effect of the dipeptide glycyl-D-
asparagine at low concentrations against aggregation of Interferon-alpha-2A upon exposure to 
freezing-thawing and shaking stress[10]. We found that the dipeptide would bind to the protein at a 
µM affinity and reduces particle formation at low concentration (6.25 mM), hinting at a stabilization 
through a stoichiometric interaction. The compound was discovered through a virtual screen that 
targeted the hydrophobic and solvent exposed residue Phe27. This residue is involved in the 
interaction between interferon-alpha-2 and interferon-alpha-receptor 2 (Figure 1, PDB entry 3S9D) 
[11]. A potential risk of stoichiometrically acting excipients is that the protein drug-excipient complex 
does not disassociate after drug administration, thus potentially altering the drug’s efficacy. The 
lifetime of the protein-excipient complex is therefore a crucial parameter to consider when developing 
stoichiometrically binding excipients. A short lifetime means that the protein-excipient complex 
disassociates rapidly. As the excipient is much smaller than the protein, it will distribute, metabolize 
and clear much faster than the protein after administration. In the case of the dipeptide presented 
here, its metabolism is facilitated further due to the presence of a peptide bond prone to enzymatic 
hydrolysis [12]. Its low molecular weight compared to that of IFN will lead to a fast clearance through 
the kidneys [13]. A long lifetime of the protein-excipient complex would instead result in a permanent 
occupation of the protein surface by one or more excipient molecules, potentially altering the proteins 
interaction with its target molecule, and consequently its efficacy.  
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Figure 1: Complex between Interferon-alpha-2 (violet) and Interferon-alpha-receptor-2 (green) (PDB 
entry 3S9D). The aggregation prone region (APR) targeted by the excipient (red) to inhibit interferon-
alpha-2a aggregation coincides with the binding site to the receptor. 
 
The occupation of a protein by a ligand is the result of the simultaneously occurring binding and 
unbinding processes [14]. When considering the equilibrium reaction between Protein 𝑃 and ligand 𝐿 
to form a complex 𝑃𝐿 (Equation 1), the rates of binding, 𝑟𝑜𝑛, and unbinding,  𝑟𝑜𝑓𝑓 can be defined as 
the product of a rate constant 𝑘 and the concentration of the reactants (Equation 2, Equation 3). 
 
𝑃 + 𝐿 ⇌ 𝑃𝐿 Equation 1 
𝑟𝑜𝑛 = 𝑘𝑜𝑛  ∙ [𝑃] ∙ [𝐿] Equation 2 
𝑟𝑜𝑓𝑓 = 𝑘𝑜𝑓𝑓  ∙ [𝑃𝐿] Equation 3 
 
Here, 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 are the rate constants for the corresponding binding and unbinding reactions and 
[𝑃], [𝐿], [𝑃𝐿] are the concentration of the protein, ligand and protein ligand complex respectively. 
In order to estimate the lifetime of a protein-ligand complex, the residence time 𝜏 can be calculated 
from the inverse of the off-binding rate constant 𝑘𝑜𝑓𝑓 (Equation 4) [15]. 
 
𝜏 =
1
𝑘𝑜𝑓𝑓
 
Equation 4 
 
Aggregation prone region 
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Computational simulations are a popular mean to study protein-ligand interactions, as they allow to 
gain insights on the interaction with atomic detail. Interactions between the excipients mannitol, 
sucrose, trehalose and sorbitol and  a ligase and a Fab fragment have previously been studied by 
docking calculations [16]. In this work a correlation between calculated binding affinity of excipients 
to the protein and Tm was observed. The Tm experiments were, however, conducted at excipient 
concentrations ranging from 145 to 220 mM, which may hint at a stabilization by preferential 
exclusion. A method that combines protein-protein and protein-excipient docking combined with 
molecular dynamics (MD) simulations to discover new excipients is described as well in a patent 
application  [17]. It aims at identifying excipients that bind to regions involved in protein self-
association in order to reduce protein aggregation. It does not state how protein aggregation is 
measured experimentally and does not relate simulation data to data from experiments on protein 
aggregation. It does furthermore not yield any novel excipients but is limited to commonly employed 
stabilizing substances such as amino acids. 
MD simulations are a mean to study protein ligand interactions at atomic detail, where each atom is 
treated as a classical particle and interactions between these particles are defined in force fields[18]. 
Shukla and Trout used MD simulations to determine the preferential interaction coefficient of a protein 
in aqueous arginine solutions of 250 to 2500 mM [19]. The study of stoichiometric binding by molecular 
dynamics is most commonly reported in the context of small molecule drug discovery. Analysis of 
molecular trajectories, which are often collected in parallel setups is challenging and can introduce 
errors due to biases in the starting structure and introduced restraints intended to enhance sampling 
of rare transitions. Markov state theory has been used in trajectory analysis to eliminate these biases 
and accurately describe the mechanism of protein-ligand interactions [20]. Markov state theory serves 
to model transitions between discrete states. The modeled process is considered memoryless, 
meaning that if the system is in a specific state, its future state does not depend on the system’s 
history. The publicly available EMMA and HTMD programs drastically facilitate the construction of 
Markov state models from MD trajectories [21]. In order to construct a Markov state model, MD 
trajectories have to be discretized. Discretization for Markov state model generation has been shown 
to work best when the dimensionality of the trajectory data is reduced. In an MD simulation, each 
simulated atom is described by three cartesian coordinates indicating its position, and three cartesian 
velocities, indicating its current movement in three-dimensional space. One frame of an MD trajectory 
therefore consists of 6N dimensions, where N is the number of simulated atoms. By identifying a set 
of features of lower dimensionality, such as dihedral angles or the distance between the ligand and 
each protein residue, the complexity of an MD trajectory can be reduced, but the information of 
interest, e.g. protein conformation or protein ligand binding, is preserved. Mathematical approaches 
to reduce the dimensionality of a matrix are principle component analysis, which preserves the highest 
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degree of variance or time lagged independent component analysis which preserves the highest 
degree of kinetic variance. The first principal component will therefore describe the motion of highest 
amplitude, while the first time lagged independent component will describe the slowest transition. 
After reduction of dimensionality, the data set of reduced dimensionality has to be discretized by a 
clustering algorithm. Finally, the transition probabilities between the clustered states can be calculated 
and experimental observables can be derived. Detailed descriptions on the workflow to construct a 
Markov model has been published by the developers of EMMA[22].  
To our knowledge, Markov state theory has not yet been employed to describe protein-excipient 
interactions. Here we use a Markov state model to investigate the mechanism of interaction between 
the stabilizing dipeptide glycyl-D-asparagine and Interferon-alpha-2A, to elucidate interaction sites and 
to estimate the residence time of the formed protein-excipient complex. 
Methods 
System setup and simulation 
Each randomized starting systems was constructed using HTMD [23]. One of 24 structures from PDB 
entry 1ITF was randomly selected using NumPy’s random.choice function [24].  The protonation states 
of the protein were adjusted to pH 7.0. The protein was centered and randomly rotated. Subsequently 
the ligand was centered, randomly rotated and placed at a random distance between 6 to 11 Å away 
from the furthest protein atom along the x-axis (Figure S 1). The ligand was again rotated randomly 
around the origin. The system was then solvated with an additional 5 Å buffer. Finally, two disulfide 
bridges were built. 
The ligand was parametrized using GAFF2 for bonded and non-bonded parameters. Atomic partial 
charges were calculated with Gaussian 16 (Gaussian Inc., Wallingford, CT, U.S.A.) and fitted with the 
RESP procedure in antechamber. Each system was minimized and equilibrated prior to the production 
run. Minimization was performed using pmemd on CPUs, whereas molecular dynamics simulations 
were performed on GPUs using pmemd.cuda implemented in Amber 18 [25–28]. A cutoff of 9 Å was 
defined for nonbonded interactions. The first 5000 cycles of minimization used the steepest descent 
algorithm, followed by 5000 cycles using the conjugate gradient algorithm. MD simulations were run 
using Langevin dynamics with a collision frequency of 1 ps-1[29]. The SHAKE algorithm was used to 
allow for timesteps of 2 fs[30]. 
Equilibration followed the scheme described by Henriksen et al. and consisted of three steps [31]. For 
1 ps, no pressure scaling was used and the temperature was set to 10 K. The system was then heated 
to 300 K within 100 ps. The last stage consisted of 50 equilibration cycles of 100 ps, each using a Monte 
  
  
7 
Carlo barostat set to atmospheric pressure. Production was performed using the NVT ensemble, 
running 60 ns per trajectory. 600 trajectories were generated in total. 
Data analysis 
A Markov State Model was constructed using HTMD which builds on PyEMMA. We followed a stepwise 
approach based on the multiple tutorials accompanying HTMD and PyEMMA. Trajectories were first 
stripped of all water, sodium and chloride. The selected featurization scheme to study the protein-
ligand interaction was the pairwise, residual, minimum distance between each protein residue and the 
dipeptide, considering only heavy atoms. The data was then projected on the first 10 time-lagged 
independent components with a lag time of 1 ns. The projected data was then clustered into 60 micro-
states using the k-means algorithm. A Markov state model was constructed with a lag time of 10 ns 
and the micro-states were clustered to 5 macro-states using PCCA++. The model was validated using 
the Chapman-Kolmogorov (CK) criterion. If the model fulfills the CK criterion, the occupation of future 
states is independent of past states, i.e. the model is markovian. (Figure S 2). Statistical errors of 
thermodynamic and kinetic quantities were obtained from 1000 bootstrapping cycles retaining 80% of 
the data. Structures were rendered using PyMOL. 
Identification of aggregation prone regions 
Three different methods were used to identify aggregation prone regions on the surface of Interferon-
alpha-2A: Aggrescan3D[32], AggScore[33] and CamSol[34]. For Aggrescan3D and CamSol the scores 
were calculated by submitting the first frame of PDB entry 1ITF to the corresponding webserver. The 
aggregation propensity according to the AggScore method was calculated using Schrödinger’s Maestro 
software using the same structure file as for the 2 other methods. Aggregation prone residues 
identified through any of the methods are residues 16, 27, 61,65, 86, 89, 98, 99, 100, 101, 102, 103, 
106, 109, 110, 111, 116, 117, 128, 129, 137.   
Results 
From the constructed Markov model, 5 macro states were identified. State 5 comprises mostly 
unbound and non-specifically associated structures. States 0 to 4 show specific regions of interaction 
between the dipeptide and INF with different degrees of fuzziness. Macro-state 0 involves interactions 
with residues 41, 42, 43, 46, 48, 51, 114, 115, 164. Macro-state 1 can be characterized by interactions 
with residues 3, 40, 41, 45-49, 155-165. For Macro-state 2, residues 5-10, 13, 90, 91, 93, 94, 96, 147 
were identified. In macro-state 3, the dipeptide is in contact with residues 33-38, 40, 41, 42, 46, 114, 
118, 121, 122, 125, 146, 149, 165. Macro-state 4, which is the least fuzzy one, only involves residues 
22, 23, 73, 75-78 (Figure 2). While the study of protein conformation was not the scope of this study, 
we observed high flexibility in the N-terminal and the C-terminal loop region as was already described 
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previously [24]. Interactions with the C-terminus are consequently present in multiple of the macro-
states. When comparing the binding sites to aggregation prone regions identified on the protein 
surface, we find that macro-state 0 and 2 show an interaction close to the aggregation prone residues 
98 to 100 (predicted by Aggrescan3D, AggScore, CamSol). Macro-state 3 shows an interaction in close 
proximity to the aggregation prone residues 27 (predicted by Aggrescan3D, AggScore, CamSol), 128 
and 129 (predicted by AggScore).  Macro-state 4 shows binding in proximity to aggregation prone 
residue 137 (predicted by AggScore).  
Macro-state 0 
  
Macro-state 1 
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Macro-state 2 
  
Macro-state 3 
  
Macro-state 4 
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Macro-state 5 
  
Figure 2: Representative structures from two perspectives at 180° rotation of macro-states defined by 
the constructed Markov model. Aggregation prone residues: 16, 27, 61,65, 86, 89, 98, 99, 100, 101, 
102, 103, 106, 109, 110, 111, 116, 117, 128, 129, 137.   
When comparing the docked structure that led to the discovery of the dipeptide as protein stabilizing 
substance, one observes a similarity to macro-state 3.  In both, the docked pose as well as in macro-
state 3, interactions with residues 33, 34 and 146 are observed. The interaction between ARG 33 and 
the dipeptide in both cases consists of a salt bridge between the residue’s side chain and the 
dipeptide’s carboxyl group (not depicted for macro-state 3). In the docked pose, the interaction with 
residue 34 is between the backbone carbonyl group and the dipeptides N-terminal amine. In the MD 
simulation, the amide nitrogen of residue 34 interacts with the dipeptide’s amide carbonyl group. The 
docked pose suggests a hydrogen bond between the side chain carboxyl of GLU146 and the dipeptide’s 
amine, which is also observed in the third macro-state.  The docked pose shows the ASN side chain of 
the dipeptide forming a hydrogen bond with the backbone carbonyl of ALA145, which is not the case 
in the structures sampled from macro-state 3 (Figure 3). 
Docked pose Structure sampled from macro-state 3 
  
 
GLU 146 
HIS 34 HIS 34 
GLU 146 
ARG 33 
GLU 165 
 
GLY-D-ASN 
 
GLY-D-ASN 
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Figure 3: Comparison of docked pose with the most similar structure of those sampled from macro-
state 3. Interacting residues are represented as sticks. 
The Markov model exposes the binding path of the dipeptide, which most frequently transitions from 
macro-state 5 to 4, occasionally passing through state 3, which acts as an intermediate. The very 
infrequently occupied states 0, 1 and 2 are all connected to state 3 and are occasionally visited before 
the dipeptide moves along to states 3 and 4. The predicted residence time is calculated to be 0.03 µs 
and the equilibrium dissociation constant shows a weak binding of 29 mM compared to the µM affinity 
observed experimentally[10]. 
Table 1: Observables derived from the Markov model and experimentally observed dissociation 
constant for the interaction between IFN and Gly-D-Asn. 
kon 313 ± 201 µM-1 s-1 
koff 30 ± 16 µ s-1 
τ 0.03 ± 0.02 µ s 
KD 29 ± 12 mM 
KD experimental 0.11 mM ± 0.02 mM 
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Figure 4: Markov processes can be visualized as a network of macro-states. Each circle represents a 
macro-state, which in our case corresponds to the ligand occupying a specific binding site (macro-states 
0-4) or being unbound (macro-state 5).  The areas of the circles are proportional to the stationary 
probability of the macro-state. Transitions between macro-states are visualized by arrows. Their 
thickness represents the probability of the transition to occur. The transition probability is also written 
on top of the arrows. The committor probability describes how likely it is that the system changes to 
the target state 4 (sink), or to the original state 5 (source). If the committor probability is close to 1, the 
system will move towards the sink. If it is close to 0, the system will move towards the source. One can 
therefore conclude that when the ligand is bound to the protein in one of the four macro-states, it will 
most likely unbind (i.e. transition to macro-state 5) before occupying another bound macro-state. 
Discussion 
Here, we use Markov theory for the first time to describe the interaction between a stabilizing small 
molecule and a therapeutic protein. The use of molecular dynamics simulations to study the 
interaction had two purposes. On the one hand, we wanted to identify the excipient’s favored 
interaction sites and compare it to the protein’s aggregation prone regions. On the other hand, we 
wanted to estimate the residence time of the protein-ligand complex to rule out any effect of the 
excipient on the drug protein’s efficacy after administration. 
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We identified five meta-stable interaction sites showing hydrogen bonding and salt-bridges between 
the protein and the dipeptide, supporting the finding of stoichiometric binding between thee protein 
and the ligand. The protein-ligand complex formed in macro-state 3 is similar to the one that was 
proposed by our previously reported virtual screen[10]. In our Markov model, the macro-state 3 is, 
however, only a weakly populated intermediate state. Despite substantial sampling, we were not able 
to reproduce the experimentally observed dissociation constant. We can consequently conclude, that 
the simulations do not elucidate the interaction process in its entirety. 
We find that in all 5 bound macro-states, the binding site is in proximity to at least one aggregation 
prone region. Considering the overall hydrophobicity of Interferon-alpha-2A and the implied presence 
of multiple of such aggregation prone regions, it seems difficult to consider this observation to be 
significant, since almost any binding site is likely to be close to an aggregation prone region. Therefore, 
the simulations on the one hand support our hypothesis of stabilization by stoichiometric binding, on 
the other hand it neither proves nor disproves that the proximity to an aggregation prone region is the 
cause for the stabilization. Obtaining a crystal structure of the protein-ligand complex would be highly 
desirable to further evaluate the model. 
The residence time estimated by our model is extremely low, indicating that there is no threat to an 
altered efficacy caused by a specific protein-excipient interaction since the complex will rapidly 
disassemble after administration. Since diffusion and distribution of small molecules is of orders of 
magnitudes faster than that of proteins, equilibrium conditions after administration are no longer 
given. Considering the underestimation of the dissociation constant, a higher residence time than the 
one calculated could nevertheless be plausible.  
Conclusion 
We studied the interaction between the stoichiometric stabilizer glycyl-D-asparagine and Interferon-
alpha-2A through the construction of a Markov state model from MD simulations. The binding 
mechanism is complex and involves interaction sites in proximity to aggregation prone regions. The 
calculated residence time is of 0.03 µs and does therefore emphasize the improbability of a distorted 
efficacy of the drug protein caused by a stoichiometric stabilizer. 
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Supplementary Information 
 
Figure S 1: Overlay of the position of the dipeptide in the starting structure for all 1000 simulations. 
Each dot represents the starting position of the ligand in the respective simulation. 
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Figure S 2: Chapman-Kolmogorov (CK) test to confirm markovianity of the constructed model. The CK 
test reveals that the markovianity of the model is given for 50 time steps. 
